Wu YT, Ru ZQ, Peng Y, Fu Z, Jia QY, Kang ZJ
In that previous study (which enrolled 377 T2DM and 4741 nondiabetic controls), the prevalence of insomnia in T2DM patients was significantly higher than in nondiabetic controls, in which the prevalence of insomnia was only 12.2% [2]
According to previously assigned interval groups (7, 15, 30, 90, 180, and 360 days), the animals were sacrificed with an overdose of 3% isoflurane
Dosing is extrapolated from preclinical models [1] [6]
While not yet FDA-approved as a standalone agent, cagrilintide peptide therapy is being investigated for: Obesity treatment Metabolic syndrome management Adjunctive therapy for GLP-1 agonist non-responders Research in combination with emerging agents like retatrutide Note: As of 2025, cagrilintide is still considered a research compound in many jurisdictions
Lee, G., Lee, Y., Shin, H., Kang, K., Park, M., Kim, K., Kwon, O., & Lee, J